| ²é¿´: 1242 | »Ø¸´: 3 | |||
| ¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß ivers12 µÄ 9 ¸ö½ð±Ò | |||
ivers12Ìú¸Ëľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
»ùÒò¶¾ÐÔÔÓÖÊÑо¿
|
||
|
Çë½ÌÒ»¸öÎÊÌ⣺ Èç¹ûÒ©µäÖеÄij¸öÒÑÖªÔÓÖÊ£¬º¬ÓкÍAPI²»Í¬µÄ¾¯Ê¾½á¹¹£¬ÊÇ·ñÐèÒª°´ÕÕ»ùÒò¶¾ÐÔÔÓÖÊÑо¿£¨ÕâÀïÔݲ»ÌÖÂÛÊÇ·ñÐèÒªÈí¼þÔ¤²â£¬Ö»¿´¾¯Ê¾½á¹¹£© ·ÖΪÁ½ÖÖÇé¿ö£º 1¡¢Ò©µäÖÐÃ÷È·¸ÃÔÓÖʵÄÏÞ¶È 2¡¢Ò©µäÖÐδÃ÷È·¸ÃÔÓÖʵľßÌåÏÞ¶È Ó¦¸ÃÈçºÎ´¦ÀíÄØ£¿ |
» ²ÂÄãϲ»¶
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖÖÐÐÄÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ10È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ168È˻ظ´
ÖйúÒ½Ò©ÐÐÒµ·¢Õ¹ÏÖ×´£º±ê×¼Æ·ÍÆ¶¯Ò©Æ·¼ì²âˮƽÌáÉý
ÒѾÓÐ1È˻ظ´
±ê׼ƷµÄ´¿¶È¶ÔÓÚÒ©Æ·ÖÊÁ¿µÄÓ°ÏìÓжà´ó£¿
ÒѾÓÐ0È˻ظ´
ÈçºÎÖÆ±¸·ûºÏ¼¼ÊõÒªÇóµÄÒ©Æ·±ê׼Ʒ£¿
ÒѾÓÐ0È˻ظ´
¶ÔÕÕÆ·ÔÚÒ©Æ·Ñз¢ÖеIJ»¿É»òȱÐÔ
ÒѾÓÐ0È˻ظ´
±ê׼ƷµÄ·ÖÀàºÍÓÃ;£¬ÄãÖªµÀ¶àÉÙ£¿
ÒѾÓÐ0È˻ظ´
ÔÓÖʶÔÕÕÆ·¼Û¸ñÈçºÎ½ç¶¨ºÍÕýȷʹÓ÷½·¨
ÒѾÓÐ0È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´

Alian2013
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 268.8
- Ìû×Ó: 17
- ÔÚÏß: 18.5Сʱ
- ³æºÅ: 2318463
- ×¢²á: 2013-03-04
- ÐÔ±ð: MM
- רҵ: É«Æ×·ÖÎö
¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ivers12: ½ð±Ò+1 2022-01-24 13:18:10
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ivers12: ½ð±Ò+1 2022-01-24 13:18:10
| ÔÓÖÊ»¹ÓкÍAPI²»Í¬µÄ»ùÒò¶¾¾¯Ê¾½á¹¹£¬Ó¦¸Ã°´M7ÖеĵÚÈýÖÖÇé¿ö½øÐлùÒò¶¾Ñо¿£¬ÈçÈôICH¸ø³öÔÓÖÊÏÞ¶È£¬¿É°´ÕÕ¸ø³öµÄÏÞ¶ÈÑо¿£¬ÈçÈôûÓиø³öÔÓÖÊÏÞ¶È£¬¿ÉÒÔ¸ù¾ÝICH¸ø³öµÄʹÓÃʱ¼äÖÜÆÚ¶ÔÓ¦µÄPDEºÍ×î´óÓÃÒ©Á¿¼ÆË㣬Ҳ¿ÉÒÔ°´ÕÕ1.5ug/ÌìµÄPDEÓÃÒ©Ñо¿£¬·çÏÕ×îµÍ¡£ |

2Â¥2022-01-18 15:36:10
ivers12
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 8769.6
- É¢½ð: 1
- Ìû×Ó: 259
- ÔÚÏß: 137.9Сʱ
- ³æºÅ: 3257324
- ×¢²á: 2014-06-05
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
|
±ÈÈçÕâ¸öBPÖеģº Limits: ¡ª impurity A: maximum 0.2 per cent; ¡ª impurity F: maximum 0.15 per cent; ¡ª unspecified impurities: for each impurity, maximum 0.10 per cent; ¡ª total: maximum 0.4 per cent; ¡ª reporting threshold: 0.05 per cent. Specified impurities A, F. Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D, E. ÕâÖÖÇé¿öÏ£¬ÔÓÖÊA£¬ÔÓÖÊF£¬ºÍÔÓÖÊB£¨º¬¾¯Ê¾½á¹¹£©µÄÏÞ¶ÈÈçºÎ½ç¶¨£¿ |

3Â¥2022-01-27 13:32:03
mrzhl1986
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 211 (´óѧÉú)
- ½ð±Ò: 1258.4
- É¢½ð: 264
- ºì»¨: 13
- ɳ·¢: 4
- Ìû×Ó: 1020
- ÔÚÏß: 411.2Сʱ
- ³æºÅ: 1019119
- ×¢²á: 2010-05-15
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

4Â¥2022-02-08 17:38:39














»Ø¸´´ËÂ¥